Skip to main content
. 2022 Jun 28;41(3):541–554. doi: 10.1200/JCO.21.02698

FIG 3.

FIG 3.

rwTTNT and OS in patients with documented first-line mantle cell lymphoma treatment from the Flatiron cohort (A) overall and by age and (B) by treatment (BR, R-CHOP, and cytarabine). BR, bendamustine plus rituximab; NE, not estimable; OS, overall survival; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; rwTTNT, real-world time to next treatment.